Cargando…
Novel strategies in the use of lopinavir/ritonavir for the treatment of HIV infection in children
Lopinavir/ritonavir (LPV/r) is considered by many as the first choice protease inhibitor (PI) for children. This co-formulation avoids the need for children to take ritonavir separately to “boost” the levels of lopinavir. LPV/r has high virologic potency, an excellent toxicity profile and a high bar...
Autores principales: | Martinez, Beatriz Larru, Riordan, F Andrew I |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3218684/ https://www.ncbi.nlm.nih.gov/pubmed/22096385 |
Ejemplares similares
-
Lopinavir/ritonavir in the treatment of HIV-1 infection: a review
por: Chandwani, Ashish, et al.
Publicado: (2008) -
Once vs. twice-daily lopinavir/ritonavir in HIV-1-infected children
Publicado: (2015) -
Population pharmacokinetics of lopinavir and ritonavir in combination with rifampicin-based antitubercular treatment in HIV-infected children
por: Zhang, C, et al.
Publicado: (2010) -
Lopinavir/ritonavir: Repurposing an old drug for HIV infection in COVID-19 treatment
por: Magro, Paola, et al.
Publicado: (2021) -
Pharmacokinetics and safety of rifabutin in young HIV-infected children receiving rifabutin and lopinavir/ritonavir
por: Moultrie, Harry, et al.
Publicado: (2015)